Company news

CelLBxHealth plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ovarian cancer study patient enrolment completed

April 26, 2021

First large-scale pharma services contract secured

April 16, 2021

ANGLE's Parsortix system showcased at AACR 2021

April 12, 2021

Global launch of clinical services laboratories

March 30, 2021

Parsortix-harvested CTCs uncover novel biomarker

February 18, 2021

Parsortix: Dynamic assessment of patient response

February 8, 2021

Parsortix demonstrates high capture rate of CTCs

January 29, 2021

Research confirms high performance of Parsortix

January 20, 2021

Change of Auditor

January 12, 2021

Parsortix can capture single cancer cell in sample

December 9, 2020

Result of General Meeting

November 13, 2020

Result of Placing & Notice of General Meeting

October 27, 2020

Submission accepted by FDA for substantive review

October 20, 2020

ANGLE announces completion of FDA submission

September 28, 2020

Potential treatment strategy to limit metastasis

September 23, 2020

Notification of Interim Results and Webcast

September 2, 2020

Result of 2020 Annual General Meeting

August 27, 2020

Parsortix use to assess response to immunotherapy

August 14, 2020

Notice of AGM and Posting of Annual Report

August 5, 2020

Study: Parsortix use in metastatic breast cancer

July 20, 2020

Blood donations recommenced for FDA studies

June 22, 2020

CTC potential as biomarker in MET inhibitor trials

May 12, 2020

Leading cancer centre publishes Parsortix workflow

May 4, 2020

Business Update

April 28, 2020

Parsortix performance in head and neck cancer

April 17, 2020

COVID-19 business impact update

March 31, 2020

Assessing risk of brain metastasis in lung cancer

March 3, 2020

Parsortix outperforms other CTC systems in RCC

February 27, 2020

ANGLE announce Tri-Con presentation with BioView

February 25, 2020

Data demonstrates key advantages of Parsortix

February 17, 2020

Study demonstrates Parsortix potential in melanoma

February 11, 2020

Change of accounting reference date

January 30, 2020

Successful face-to-face meeting with FDA

January 22, 2020

Cancer centre shows Parsortix use in melanoma

November 7, 2019

Q-submission to FDA containing headline data

October 30, 2019

Notice of AGM

October 8, 2019

European patent granted for megakaryocyte analysis

October 4, 2019

Use of Parsortix in head and neck cancer

September 13, 2019

Research with Parsortix in prostate cancer

September 10, 2019

Parsortix for Neuroendocrine Analysis in SCLC

September 4, 2019

Initiation of Ovarian Cancer Study

August 29, 2019

Prelim Results for the year ended 30 April 2019

July 31, 2019

Use of Parsortix for single cell analysis of CTCs

July 22, 2019

Result of General Meeting anf Total Voting Rights

July 12, 2019

Result of Placing

June 25, 2019

Parsortix used to investigate immunotherapy target

June 21, 2019

Completion of Ovarian Cancer Pre-Study

June 5, 2019

Positive Results from FDA Clinical Study

May 31, 2019

Immune suppressor cells promote metastasis

April 26, 2019

Parsortix used in new cancer assessment technique

April 18, 2019

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 30 decks. Every deck is listed under its year.